Daveen Chopra - 07 May 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: CVP, TMTT & Surgical
Issuer ticker: EW
Reported as of: 07 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2026, 21:16:28 UTC
Prior SEC filing: 04 May 2026
Next SEC filing: 12 May 2026
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Daveen Chopra filed Form 4 for Edwards Lifesciences Corp (EW) on 08 May 2026.

Key facts

This page summarizes Daveen Chopra's Form 4 filing for Edwards Lifesciences Corp (EW).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 May 2026, 21:16.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001740963 Primary reporting owner

Chopra Daveen

Relationship: CVP, TMTT & Surgical
Address: ONE EDWARDS WAY, IRVINE
Signature: Linda J. Park, Attorney-in-Fact
Signature date: 08 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Award

Transaction value
Shares: +9,675
Change %: +30%
Price: $0.000000^*
Shares after: 41,594
Date: 07 May 2026
Ownership: Direct
Footnotes: F1

EW transaction

Common Stock

Tax liability

Transaction value
Shares: -674
Change %: -1.6%
Price: $83.20^*
Shares after: 40,920
Date: 07 May 2026
Ownership: Direct

EW transaction

Common Stock

Tax liability

Transaction value
Shares: -1,141
Change %: -2.8%
Price: $82.76^*
Shares after: 39,779
Date: 08 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Award

Transaction value
Shares: +49,100
Change %
Price: $0.000000^*
Shares after: 49,100
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,100
Exercise price: $82.76
Footnotes: F2

EW transaction Derivative

Performance Rights

Award

Transaction value
Shares: +9,675
Change %
Price: $0.000000^*
Shares after: 9,675
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,675
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F2

These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F3

Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.